文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

流行病中化学预防试验设计:COVID-19研究注册的系统评价启示

Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.
PubMed 文献 · Trials · 2021-05-29

该系统评价检索了疫情前21周国际试验注册库,纳入76项COVID-19化学预防研究注册(计划入组208,367人)。多数试验在流行病学设定的发病率下检验效能不足,且设计启动滞后于疫苗研发,国际协调与适应性平台设计亟待加强。

要点

  • 76项注册中63项为随机设计,仅1项采用适应性设计。
  • 以对照组发病率10%计,66%试验无法检出50%效果量。
  • 医护人员占靶人群65.8%,老年人仅3.8%研究关注。

核心结论

  • 许多注册的COVID-19化学预防效力试验在流行病学设定的发病率下检验效能不足,难以检出有临床意义的保护效果。
  • 试验组织速度远慢于疫苗研发,使其重要性降低,亟需国际协调机制与合作。
  • 应支持早期采用适应性平台试验设计,以结构化纳入和退出候选药物并快速搭建试验基础设施。

研究设计与样本

  • 纳入评估COVID-19化学预防药物效力的试验方案,共发现76项化学预防研究注册。
  • 计划入组总人数208,367人,中位样本量490(IQR 262-1710);63项为随机设计,61项设对照组,对照组总计划入组197,010人,中位600(IQR 236-1834)。

主要发现

  • 仅4项方案提供了所寻求效应量的信息。
  • 估计对照组发病率10%时,66%试验无法检出50%效应量,97%试验无法检出30%效应量(80%检验效能水平)。
  • 仅1项试验注册显示适应性设计证据。
  • 主要结局最常见为实验室确诊感染(有或无临床症状);46%试验仅用PCR检测,6.6%仅用血清学检测,14.5%两者均用。

关键数值与推荐

  • 纳入标准:评估COVID-19化学预防药物效力的试验方案。
  • 检验效能评估条件:对照组发病率10%,检验效能80%水平,效应量50%或30%。

临床怎么用

  • 化学预防试验设计应基于流行病学设定的发病率进行检验效能计算,确保能检出临床意义的保护效果。
  • 优先采用适应性平台试验设计,实现候选药物的结构化纳入与退出及试验基础设施快速搭建。
  • 加强国际协调与合作,早期启动大规模、可行性强的化学预防试验。

局限性

  • 仅检索疫情前21周注册的试验方案,后续注册试验未纳入。
  • 仅4项方案提供效应量信息,检验效能估计基于假设条件。
  • 未报告试验实际执行与完成情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemoprophylactics against emerging epidemic and pandemic infectious diseases offer potential for prevention but require efficacy and safety analysis before widespread use can be recommended. Chemoprophylaxis with repurposed drugs enables deployment ahead of development of novel vaccines. It may have particular utility as a stopgap ahead of vaccine deployment or when vaccines become less effective on virus variants, in countries where there may be structural inaccessibility to vaccines or in specific risk-groups. Rapid implementation of robust trial designs is a persistent challenge in epidemics. We systematically reviewed SARS-CoV-2 and COVID-19 chemoprophylaxis trial registrations from the first 21 weeks of the pandemic to critically appraise significant design features and alignment of study populations to clinical and public health uses, and describe candidate chemoprophylactic agents. METHODS: We searched online international trial databases from 31 Dec 2019 to 26 May 2020 using keywords "proph*" or "prevention". Trial protocols assessing efficacy of chemoprophylactic agents for COVID-19 were included. Trial components were screened for eligibility and relevant studies extracted. Key trial design features were assessed. RESULTS: We found 76 chemoprophylaxis study registrations, proposing enrolment of 208,367 people with median size of 490 (IQR 262-1710). A randomised design was specified for 63 trials, 61 included a control group and total proposed enrolment size was 197,010, median 600 (IQR 236-1834). Four protocols provided information on effect size sought. We estimate that for a control group attack rate of 10%, 66% of trials would be underpowered to detect a 50% effect size, and 97% of trials would be underpowered to detect a 30% effect size (at the 80% level). We found evidence of adaptive design in one trial registration only. Laboratory-confirmed infection with or without symptoms was the most common primary outcome. Polymerase chain reaction testing alone was used in 46% of trials, serological testing in 6.6% and 14.5% used both testing methods. Healthcare workers were the target population in 52/79 (65.8%) trials: 49 pre-exposure prophylaxis (PrEP) and 3 post-exposure prophylaxis (PEP). Sixteen trials (20.3%) planned PEP in close contacts. Five studies (6.3%) considered chemoprophylaxis in clinical-risk patients. Older adults were the focus of recruitment in only 3 (3.8%) studies (all long-term care facilities). Two (2.5%) studies of PrEP in the general population included older adults. Hydroxychloroquine was the most common candidate agent in 55/79 trials (69.6%), followed by chloroquine (4/79, 5.0%) and lopinavir/ritonavir (3/79, 3.8%). CONCLUSION: Many registered COVID-19 chemoprophylaxis efficacy trials were underpowered to detect clinically meaningful protection at epidemiologically informed attack rates. This, compounded with the time that has taken to organise these trials as compared to the rapid development of COVID-19 vaccines, has rendered these trials of marginal importance. International coordination mechanisms and collaboration is required. Supporting the design of feasible chemoprophylaxis trials, large enough to generate strong evidence, early on in an epidemic using adaptive platform trial designs will allow structured entry and exit of candidate agents and rapid stand-up of trial infrastructure. REVIEW PROTOCOL REGISTRATION: Our protocol is registered at https://www.osf.io/vp56f on May 20, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Manoharan L, Olliaro P, Horby PW, et al. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. Trials. 2021. PMID: 34051840. doi:10.1186/s13063-021-05323-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。